Rapport Therapeutics, Inc. (RAPP)
$48.81-$2.06 (-4.05%) Today
Abraham Ceesay - Officer
Krishnaswamy Yeleswaram - OfficerKrishnaswamy Yeleswaram - OfficerKrishnaswamy Yeleswaram - OfficerKrishnaswamy Yeleswaram - OfficerAbraham Ceesay - OfficerAbraham Ceesay - OfficerAbraham Ceesay - OfficerRapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 20 | 149,624 | $7.09M |
| Grant or award | 8 | 121,600 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
61 Form 4 filings on record, the earliest from Nov 7, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 18,921 | $49.57 | $938K | |
| Krishnaswamy Yeleswaram - Officer | Open-market sale | Common Stock | 13,160 | $50.00 | $658K | |
| Krishnaswamy Yeleswaram - Officer | Open-market sale | Common Stock | 20,799 | $50.31 | $1.05M | |
| Krishnaswamy Yeleswaram - Officer | Open-market sale | Common Stock | 16,201 | $51.06 | $827K | |
| Krishnaswamy Yeleswaram - Officer | Open-market sale | Common Stock | 404 | $49.90 | $20K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 14,171 | $45.97 | $651K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 8,370 | $46.75 | $391K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 3,664 | $46.90 | $172K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 19,500 | $48.04 | $937K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 5,794 | $48.62 | $282K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 2,203 | $42.11 | $93K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 7 | $42.74 | $299 | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 5,481 | $39.72 | $218K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 2,729 | $40.57 | $111K | |
| Cheryl Gault - Officer | Open-market sale | Common Stock | 1,900 | $40.09 | $76K | |
| Cheryl Gault - Officer | Open-market sale | Common Stock | 3,792 | $41.39 | $157K | |
| Cheryl Gault - Officer | Open-market sale | Common Stock | 3,308 | $42.17 | $140K | |
| Cheryl Gault - Officer | Open-market sale | Common Stock | 1,000 | $43.15 | $43K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 7,344 | $39.77 | $292K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 876 | $40.34 | $35K | |
| John Maraganore | Grant or award | Stock Option (Right to Buy) | 15,200 | $0.00 | - | |
| Robert J. Perez | Grant or award | Stock Option (Right to Buy) | 15,200 | $0.00 | - | |
 Steven M. Paul | Grant or award | Stock Option (Right to Buy) | 15,200 | $0.00 | - | |
| Paul M. Silva | Grant or award | Stock Option (Right to Buy) | 15,200 | $0.00 | - | |
| James Healy | Grant or award | Stock Option (Right to Buy) | 15,200 | $0.00 | - | |
| Reid M. Huber | Grant or award | Stock Option (Right to Buy) | 15,200 | $0.00 | - | |
| Wendy B. Young | Grant or award | Stock Option (Right to Buy) | 15,200 | $0.00 | - | |
| Ramiro Sanchez | Grant or award | Stock Option (Right to Buy) | 15,200 | $0.00 | - | |
| Third Rock Ventures V, L.P. | Open-market sale | Common Stock | 18,572 | $40.05 | $744K | |
| Third Rock Ventures V, L.P. | Open-market sale | Common Stock | 133,618 | $40.24 | $5.38M | |
| Third Rock Ventures V, L.P. | Open-market sale | Common Stock | 271,495 | $40.12 | $10.89M | |
| Third Rock Ventures V, L.P. | Open-market sale | Common Stock | 5,018 | $40.31 | $202K | |
| Third Rock Ventures V, L.P. | Open-market sale | Common Stock | 426,005 | $40.32 | $17.18M | |
| Krishnaswamy Yeleswaram - Officer | Open-market sale | Common Stock | 20,225 | $39.99 | $809K | |
| Krishnaswamy Yeleswaram - Officer | Open-market sale | Common Stock | 500 | $34.98 | $17K | |
| Krishnaswamy Yeleswaram - Officer | Open-market sale | Common Stock | 9,165 | $34.97 | $321K | |
| Krishnaswamy Yeleswaram - Officer | Open-market sale | Common Stock | 10,200 | $35.08 | $358K | |
| Krishnaswamy Yeleswaram - Officer | Open-market sale | Common Stock | 360 | $34.90 | $13K | |
| Cheryl Gault - Officer | Open-market sale | Common Stock | 7,161 | $28.04 | $201K | |
| Cheryl Gault - Officer | Open-market sale | Common Stock | 2,839 | $28.55 | $81K | |
| Krishnaswamy Yeleswaram - Officer | Open-market sale | Common Stock | 10,115 | $29.99 | $303K | |
| Cheryl Gault - Officer | Open-market sale | Common Stock | 2,014 | $28.93 | $58K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 3,552 | $29.05 | $103K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 2,281 | $29.80 | $68K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 2,983 | $29.04 | $87K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 2,100 | $29.80 | $63K | |
| David Bredt - Officer | Option exercise | Common Stock | 6,000 | $1.80 | $11K | |
| David Bredt - Officer | Option exercise | Stock Options (Right to Buy) | 6,000 | $0.00 | - | |
| David Bredt - Officer | Open-market sale | Common Stock | 900 | $28.02 | $25K | |
| David Bredt - Officer | Open-market sale | Common Stock | 5,400 | $28.95 | $156K | |
| David Bredt - Officer | Open-market sale | Common Stock | 2,200 | $29.59 | $65K | |
| Jeffrey Sevigny - Officer | Grant or award | Stock Option (Right to Buy) | 130,000 | $0.00 | - | |
| Abraham Ceesay - Officer | Grant or award | Stock Option (Right to Buy) | 428,000 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| KRISHNASWAMY YELESWARAM | Officer | 37,000 | $1.83M | View on EDGAR | |
| KRISHNASWAMY YELESWARAM | Officer | 11,472 | $553K | View on EDGAR | |
| KRISHNASWAMY YELESWARAM | Officer | 2,092 | $103K | View on EDGAR |
Rapport Therapeutics, Inc. (RAPP) had 16 insider filings in the last 90 days, with the most recent on 2026-08-26. The full record for RAPP runs to 61 Form 4 filings, the earliest from 2024-11-07. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of RAPP were filed in the last 90 days. 4 purchases are on record for this company.
20 insider sales of RAPP were filed in the last 90 days, totaling $7.09M.
This page tracks RAPP Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add RAPP to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
